IACH Journal Club-Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025

Current Status

Not Enrolled

Enroll in this course to get access

Free

You don't currently have access to this content

You don't currently have access to this content

The IACH, founded by an international group of physicians whose focus is to promote good clinical practice in the field of clinical hematology

Accessing this course requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Don't have an account? Register one!

Name(Required)

First Last

Email(Required)

Country(Required)

Institution

EBAH Membership Number

Profession(Required)

Specialty

Password

Enter Password Confirm Password

CAPTCHA